Bio Key International (BKYI) Common Equity (2016 - 2025)
Bio Key International (BKYI) has disclosed Common Equity for 16 consecutive years, with $6.0 million as the latest value for Q3 2025.
- Quarterly Common Equity rose 4443.74% to $6.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Sep 2025, up 4443.74% year-over-year, with the annual reading at $3.8 million for FY2024, 254.66% up from the prior year.
- Common Equity hit $6.0 million in Q3 2025 for Bio Key International, down from $6.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $19.6 million in Q1 2021 to a low of -$1.1 million in Q2 2024.
- Historically, Common Equity has averaged $7.7 million across 5 years, with a median of $6.0 million in 2025.
- Biggest five-year swings in Common Equity: crashed 184.84% in 2024 and later skyrocketed 4443.74% in 2025.
- Year by year, Common Equity stood at $15.6 million in 2021, then crashed by 66.05% to $5.3 million in 2022, then tumbled by 79.94% to $1.1 million in 2023, then skyrocketed by 254.66% to $3.8 million in 2024, then surged by 60.26% to $6.0 million in 2025.
- Business Quant data shows Common Equity for BKYI at $6.0 million in Q3 2025, $6.9 million in Q2 2025, and $7.5 million in Q1 2025.